Molecular detection of breast cancer metastasis in sentinel lymph nodes by reverse transcriptase polymerase chain reaction (RT-PCR): identifying, evaluating and establishing multi-marker panels

被引:0
作者
Christian W. Wallwiener
Markus Wallwiener
Ralf R. Kurth
Carmen Röhm
Hans Neubauer
Malgorzata J. Banys
Annette Staebler
Birgitt Schönfisch
Stefan C. Meuer
Thomas Giese
Tanja N. Fehm
机构
[1] University of Tübingen,Department of Obstetrics and Gynaecology
[2] NCT National Centre for Cancer Diseases,Department of Pathology
[3] University of Tübingen,Institute of Immunology
[4] Marienkrankenhaus Hamburg,undefined
[5] University of Heidelberg,undefined
来源
Breast Cancer Research and Treatment | 2011年 / 130卷
关键词
Breast cancer; Sentinel lymph node biopsy; Quantitative reverse transcriptase polymerase chain reaction; Micrometastasis; Tumour-specific gene transcript(s);
D O I
暂无
中图分类号
学科分类号
摘要
The potential advantage of using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) methodology to detect metastasis in sentinel lymph nodes (SLNs) of breast cancer (BC) patients was evaluated in this prospective study. We measured the expression of relevant gene transcripts in SLNs using an innovative algorithm and compared the results of single-marker assays versus multi-marker assays with conventional histological detection methods. SLNs from women aged ≥18 years diagnosed with unilateral BC were examined by haematoxylin-eosin staining and immunohistochemistry and analysed for transcripts of several relevant genes using qRT-PCR (learning group). Four candidate panels of expressed transcript combinations with high sensitivity and specificity were selected for further investigation. The candidate panels were then validated using SLNs from a second group of BC patients (validation group). In the learning group, 74/314 SLN sections from 150 patients were positive for metastasis by histology. The transcripts analysed showed the following individual sensitivities/specificities: cytokeratin 19 (CK19) 94.6%/97.9%; mammaglobin 1 (MGB1) 82.4%/91.7%; mammaglobin 2 (MGB2) 82.4%/96.7%; carcinoembryonic antigen (CEA) 71.6%/97.5%; EPCAM (epithelial cell adhesion molecule) 91.9%/97.1%; and NY-BR-1 82.4%/93.8%. The optimal panel based on the predefined criteria comprised four markers: CK19, MGB1, EPCAM, and NY-BR-1, of which ≥2 had to be positive (95.9% sensitivity, 95.0% specificity, 85.5% positive predictive value (PPV), and 98.7% negative predictive value (NPV)). Overall concordance with histology was 95.2%. In the validation group, 84/315 SLN sections from 235 patients were histologically positive, and panel sensitivity, specificity and overall accuracy were 88.1, 95.2 and 93.3%, respectively, at the SLN section level. In conclusion, molecular staging using expression patterns of relevant transcripts in SLNs could serve as a useful complement to standard diagnostic work-up in BC patients. The proposed flexible multi-parametric approach does not improve the overall accuracy compared with the single-marker approach. However, it overcomes several limitations of the previously reported molecular assays for SLN diagnosis.
引用
收藏
页码:833 / 844
页数:11
相关论文
共 510 条
[1]  
Cheng G(2011)Current status of sentinel lymph-node biopsy in patients with breast cancer Eur J Nucl Med Mol Imaging 38 562-575
[2]  
Kurita S(2005)American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer J Clin Oncol 23 7703-7720
[3]  
Torigian DA(2006)Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial J Natl Cancer Inst 98 599-609
[4]  
Alavi A(2004)Predictors of non-sentinel lymph node metastasis in breast cancer patients Eur J Cancer 40 1731-1737
[5]  
Lyman GH(2004)Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer Br J Surg 91 1245-1252
[6]  
Giuliano AE(2009)Molecular assessment of sentinel lymph node in breast cancer management Histopathology 55 107-113
[7]  
Somerfield MR(2010)Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial Ann Surg 252 426-432
[8]  
Benson AB(2001)Occult metastases in sentinel nodes of 200 patients with operable breast cancer Ann Surg Oncol 8 675-681
[9]  
Bodurka DC(2002)Complete sectioning of axillary sentinel nodes in patients with breast cancer. Analysis of two different step sectioning and immunohistochemistry protocols in 246 patients J Clin Pathol 55 926-931
[10]  
Burstein HJ(2004)Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology J Clin Pathol 57 695-701